Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-GDM: Dapagliflozin and Metformin in Overweight Women with History of GDM
NCT02338193Phase 3Completed
- Sponsor
- Woman's
- Start
- Sep 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Woman's. Primary endpoint: Change in Body Weight at 24 weeks. Started Sep 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02338193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338193.